Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data

DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP - News) announced today that two posters describing significant preclinical studies performed by Access collaborators at two prominent institutes in France, were presented last week at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled “International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications One poster provides results of additional studies of the mechanism of ProLindac’s anticancer activity, while the second poster demonstrates the potential benefits for cancer therapy of combining ProLindac with other anticancer agents.

MORE ON THIS TOPIC